Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-Year follow-up of a prospective, randomized, phase III trial

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 4, 2005, Pages 985-990

  Wasserman, Todd H ^a   Brizel, David M ^b   Henke, Michael ^c   Monnier, Alain ^d   Eschwege, Francois ^e   Sauer, Rolf ^f   Strnad, Vratislav ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d Medical Oncology and Radiotherapy   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Amifostine; Head and neck cancer; Radiotherapy; Xerostomia

Indexed keywords

BIOMEDICAL ENGINEERING; DISEASE CONTROL; MEDICAL PROBLEMS; PATIENT MONITORING; PATIENT TREATMENT; TUMORS;

AMIFOSTINE; HEAD-AND-NECK CANCER; TUMOR CONTROL; XEROSTOMIA;

RADIOTHERAPY;

AMIFOSTINE;

ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RADIATION DOSE; RADIATION INJURY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SALIVA; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AMIFOSTINE; CARCINOMA, SQUAMOUS CELL; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; RADIATION-PROTECTIVE AGENTS; SALIVA; SURVIVAL RATE; XEROSTOMIA;

EID: 27144502687     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.07.966     Document Type: Article

References (33)

1. M.M. Morris, R.K. Schmidt-Ullrich, L. DiNardo Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas Int J Radiat Oncol Biol Phys 52 2002 918 928
2. P. Olmi, S. Crispino, C. Fallai Locoregionally advanced carcinoma of the oropharynx Conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy - a multicenter randomized trial Int J Radiat Oncol Biol Phys 55 2003 78 92
3. J.A. Ship, K. Hu Radiotherapy-induced salivary dysfunction Semin Oncol 31 2004 29 36
4. A.B. Jensen, O. Hansen, K. Jorgensen Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer Acta Oncol 33 1994 487 491
5. O.B. Wijers, P.C. Levendag, M.M. Braaksma Patients with head and neck cancer cured by radiation therapy A survey of the dry mouth syndrome in long-term survivors Head Neck 24 2002 737 747
6. J.T. Johnson, G.A. Ferretti, W.J. Nethery Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer N Engl J Med 329 1993 390 395
7. A. Eisbruch, R.K. Ten Haken, H.M. Kim Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head-and-neck cancer Int J Radiat Oncol Biol Phys 45 1999 577 587
8. R.L. Capizzi The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine Semin Oncol 26 1999 3 21
9. J.S. Rasey, Z. Grunbaum, K.A. Krohn Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913) Radiat Res 102 1985 130 137
10. S. McDonald, C. Meyerowitz, T. Smudzin Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction Int J Radiat Oncol Biol Phys 29 1994 747 754
11. D.M. Brizel, T.H. Wasserman, M. Henke Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 18 2000 3339 3345
12. J.D. Cox, J. Stetz, T.F. Pajak Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 31 1995 1341 1346
13. T. Wasserman, J.I. Mackowiak, D.M. Brizel Effect of amifostine on patient assessed clinical benefit in irradiated head-and-neck cancer Int J Radiat Oncol Biol Phys 48 2000 1035 1039
14. R.M. Nagler Short- and long-term functional vs morphometrical salivary effects of irradiation in a rodent model Anticancer Res 18 1998 315 320
15. J. Büntzel, M. Glatzel, K. Kuttner Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer Semin Radiat Oncol 12 2002 4 13
16. C.L. Bennett, D. Lane, T. Stinson Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer Preliminary results from a randomized phase II clinical trial from Germany Cancer Invest 19 2001 107 113
17. M.L. Hensley, L.M. Schuchter, C. Lindley American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants J Clin Oncol 17 1999 3333 3355
18. L.M. Schuchter, M.L. Hensley, N.J. Meropol 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants Clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 20 2002 2895 2903
19. J. Büntzel, K. Kuttner, D. Frohlich Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer Ann Oncol 9 1998 505 509
20. K.H. Bohuslavizki, S. Klutmann, W. Brenner Salivary gland protection by amifostine in high-dose radioiodine treatment Results of a double-blind placebo-controlled study J Clin Oncol 16 1998 3542 3549
21. M.I. Koukourakis, G. Kyrias, S. Kakolyris Subcutaneous administration of amifostine during fractionated radiotherapy A randomized phase II study J Clin Oncol 18 2000 2226 2233
22. D. Antonadou, M. Pepelassi, M. Synodinou Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer Int J Radiat Oncol Biol Phys 52 2002 739 747
23. J. Bourhis, R. De Crevoisier, B. Abdulkarim A randomized study of very accelerated radiotherapy with and without amifostine in head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 46 2000 1105 1108
24. P.R. Anne, W.J. Curran Jr A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer Semin Radiat Oncol 12 2002 18 19
25. D. Trog, P. Bank, T.G. Wendt Daily amifostine given concomitantly to chemoradiation in head and neck cancer. A pilot study Strahlenther Onkol 175 1999 444 449
26. M. Orditura, F. De Vita, A. Belli Efficacy and safety profile of amifostine in the preoperative combined therapy of esophageal cancer patients Oncol Rep 7 2000 397 400
27. W. Wagner, F.J. Prott, K.G. Schonekas Amifostine A radioprotector in locally advanced head and neck tumors Oncol Rep 5 1998 1255 1257
28. P. Vacha, F. Fehlauer, B. Mahlmann Randomized phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179 2003 385 389
29. M. Suntharalingam, J. Jaboin, R. Taylor The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT) Semin Oncol 31 2004 2 7
30. D.I. Rosenthal, M.S. Chambers, R.S. Weber A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing Semin Oncol 31 2004 25 28
31. W.L. Thorstad, K.S. Chao, B. Haughey Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer Semin Oncol 31 2004 8 12
32. D.R. Cassatt, C.A. Fazenbaker, G. Kifle Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model Int J Radiat Oncol Biol Phys 57 2003 794 802
33. C.M. Bachy, C.A. Fazenbaker, G. Kifle Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys Oncology 67 2004 187 193